Koen De Geest

3.4k total citations · 1 hit paper
44 papers, 2.3k citations indexed

About

Koen De Geest is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Koen De Geest has authored 44 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Reproductive Medicine, 15 papers in Oncology and 13 papers in Surgery. Recurrent topics in Koen De Geest's work include Ovarian cancer diagnosis and treatment (15 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Colorectal and Anal Carcinomas (6 papers). Koen De Geest is often cited by papers focused on Ovarian cancer diagnosis and treatment (15 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Colorectal and Anal Carcinomas (6 papers). Koen De Geest collaborates with scholars based in United States, Australia and Belgium. Koen De Geest's co-authors include Susan K. Lutgendorf, Anil K. Sood, Jeffrey M. Fowler, William P. McGuire, Mark F. Brady, Peter A. Argenta, David G. Mutch, Michael Friedländer, Robert A. Burger and Ann Marie Swart and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Koen De Geest

40 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

2009 500 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Koen De Geest United States	22	878	693	618	495	458	44	2.3k
Susan A. Davidson United States	21	1.1k 1.3×	847 1.2×	444 0.7×	426 0.9×	610 1.3×	57	2.5k
Whitfield B. Growdon United States	31	966 1.1×	616 0.9×	921 1.5×	582 1.2×	545 1.2×	139	2.7k
David Oram United Kingdom	28	2.0k 2.3×	486 0.7×	1.4k 2.3×	492 1.0×	436 1.0×	64	3.3k
Andy Ryan United Kingdom	29	910 1.0×	712 1.0×	523 0.8×	255 0.5×	1.2k 2.5×	99	3.0k
Mitchell I. Edelson United States	17	788 0.9×	450 0.6×	440 0.7×	392 0.8×	408 0.9×	42	1.8k
Marc Sütterlin Germany	33	457 0.5×	677 1.0×	803 1.3×	535 1.1×	667 1.5×	191	3.6k
Hongbo Yang United States	24	406 0.5×	443 0.6×	328 0.5×	143 0.3×	326 0.7×	136	1.9k
Thomas Buekers United States	20	346 0.4×	495 0.7×	422 0.7×	181 0.4×	441 1.0×	50	1.5k
Thomas B. Hakes United States	30	1.9k 2.2×	1.1k 1.6×	594 1.0×	1.5k 3.0×	280 0.6×	78	3.2k
Nao Suzuki Japan	29	1.4k 1.6×	424 0.6×	378 0.6×	280 0.6×	1.1k 2.3×	202	3.3k

Countries citing papers authored by Koen De Geest

Since Specialization

Citations

This map shows the geographic impact of Koen De Geest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen De Geest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen De Geest more than expected).

Fields of papers citing papers by Koen De Geest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen De Geest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen De Geest. The network helps show where Koen De Geest may publish in the future.

Co-authorship network of co-authors of Koen De Geest

This figure shows the co-authorship network connecting the top 25 collaborators of Koen De Geest. A scholar is included among the top collaborators of Koen De Geest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koen De Geest. Koen De Geest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Michael A., William E. Brady, Heather A. Lankes, et al.. (2012). A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 125(3). 635–639. 41 indexed citations

Coleman, Robert L., Charles F. Levenback, Michael A. Gold, et al.. (2012). Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecologic Oncology. 128(2). 155–159. 54 indexed citations

Brown, Jubilee, William E. Brady, Julian C. Schink, et al.. (2012). Late-Breaking Abstract 2: Bevacizumab shows activity in treating recurrent sex cord-stromal ovarian tumors: Results of a phase II trial of the Gynecologic Oncology Group. Gynecologic Oncology. 125(3). 771–772. 1 indexed citations

Lutgendorf, Susan K., Koen De Geest, David Bender, et al.. (2012). Social Influences on Clinical Outcomes of Patients With Ovarian Cancer. Journal of Clinical Oncology. 30(23). 2885–2890. 128 indexed citations

Leslie, Kimberly K., Kristina W. Thiel, Michael J. Goodheart, et al.. (2012). Endometrial Cancer. Obstetrics and Gynecology Clinics of North America. 39(2). 255–268. 42 indexed citations

Moore, Kathleen N., Michael W. Sill, David S. Miller, et al.. (2012). A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 127(3). 456–461. 24 indexed citations

Clements, Aine, Dawne N. Shelton, Soohyung Park, et al.. (2011). Lymphoid Enhancing Factor 1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancer and associations with clinical factors. 2(1). 1–2. 1 indexed citations

Usha, Lydia, Michael W. Sill, Kathleen M. Darcy, et al.. (2011). A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology. 121(3). 455–461. 46 indexed citations

Engle, Dannielle D., et al.. (2011). Lymphoid enhancing factor 1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancers and associations with clinical factors. Gynecologic Oncology. 123(2). 437–437. 1 indexed citations

10.

Mannel, Robert S., Mark F. Brady, Elise C. Kohn, et al.. (2010). GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus low-dose paclitaxel 40 mg/m(2)/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus observation in patients with early-stage ovarian carcinoma. Gynecologic Oncology. 116(3).

11.

Nolen, Brian M., Liudmila Velikokhatnaya, Adele Marrangoni, et al.. (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology. 117(3). 440–445. 126 indexed citations

12.

Monk, Bradley J., Michael W. Sill, Parviz Hanjani, et al.. (2010). Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 120(3). 459–463. 13 indexed citations

13.

Cella, David, Helen Huang, Howard D. Homesley, et al.. (2010). Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. Gynecologic Oncology. 119(3). 538–542. 30 indexed citations

14.

Bookman, Michael A., Mark F. Brady, William P. McGuire, et al.. (2009). Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology. 27(9). 1419–1425. 500 indexed citations breakdown →

15.

Merritt, William M., Yvonne G. Lin, Whitney A. Spannuth, et al.. (2008). Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth. JNCI Journal of the National Cancer Institute. 100(5). 359–372. 195 indexed citations

16.

Geest, Koen De, et al.. (2006). Metastatic choriocarcinoma to the lung coexistent with a viable pregnancy. International Journal of Gynecology & Obstetrics. 94(1). 56–57. 5 indexed citations

17.

Rose, Stephen L., Matthew P. Fitzgerald, Michael J. Hitchler, et al.. (2006). Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecologic Oncology. 102(2). 319–324. 44 indexed citations

18.

Massad, L. Stewart & Koen De Geest. (1999). Multimodality Therapy for Carcinoma of the Bartholin Gland. Gynecologic Oncology. 75(2). 305–307. 27 indexed citations

19.

Geest, Koen De, Cynthia Bergman, Mary Turyk, Brigitte Frank, & George D. Wilbanks. (1994). Differential Response of Cervical Intraepithelial and Cervical Carcinoma Cell Lines to Transforming Growth Factor-β1. Gynecologic Oncology. 55(3). 376–385. 27 indexed citations

20.

Manetta, Alberto, Edward Podczaski, James E. Larson, Koen De Geest, & Rodrigue Mortel. (1989). Scalene lymph node biopsy in the preoperative evaluation of patients with recurrent cervical cancer. Gynecologic Oncology. 33(3). 332–334. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact